Abstract:Background/Aims: As one of the mostly aggressive and fatal malignancy, gallbladder carcinoma has been known to be resistant to many anticancer drugs. Although it is under active investigation, it is still difficult to achieve satisfactory effect for most chemo-drugs on this tumor. It has previously reported that somatostatin could increase the chemosensitivity of gallbladder carcinoma cells (GBC-SD) and reduce the therapeutic dose of Doxorubicin in killing GBC-SD cells. SST could enhance the chemosensitivity of gallbladder carcinoma to Doxorubincin (DOX) by transient arresting cell cycle to S phase. We tried to clarify the mechanism by which SST utilized to enhance the chemosensitivity of GBC-SD cells to DOX. We further investigated whether the enhanced chemosensitivity of GBC-SD cells to DOX in the presence of SST is via apoptosis or cell cycle regulation. In addition, we also looked into related factors involved in cell cycle regulation and apoptosis.Methodology: Twenty-four hours after somatostatin treatment, doxorubicin was gradually added and the growth curve of GBC-SD cells was determined according to MTT test. Cell apoptosis was measured by flow cytometry (FCM) using Annexin V/ Propidium Iodide Binding. Cell cycle was also examined by FCM. The somatostatin receptor (SSTR) subtypes in GBC-SD cells were identified using immunocytochemistry and RT-PCR assay. The expressions of p53. Bax and phosphorylated RB (pRB) protein were examined using western blotting assay.Results: When GBC-SD cells were treated with SST alone, no significant cell growth inhibition and cell apoptosis were observed. SST could induce a transient S phase arrest in GBC-SD cells. The mRNA expression of SSTR1, 2, 3, 4, 5 were all detected in GBC-SD cells, whereas only SSTR1, 2, 3 were detected in GBC-SD cells using immunocytochemistry assay. After GBC-SD cells were treated with SST for 24h, the expression level of p53 and Bax protein in GBC-SD cells was similar to that of the control group, however up-regulated pRB protein expression was observed (p<0.05).Conclusions: Our results suggested that the synergistic inhibitory effect of somatostatin and doxorubicin co-treatment on GBC-SD cells was not due to SST induced apoptosis concerning the expression of p53 and Bax protein. Our data clearly showed all 5 SST receptor subtypes expressed in GBC-SD cells by RT-PCR and 3 SST receptors by immunocytochemistry. Accumulated evidence has been proved the relationship between cell cycle regulation and RB protein phosphorylation. In the chemosensitized GBC-SD cell line treated with SST, phosphorylated RB and cell cycle arrest were simultaneously manifested. We reasoned that somatostatin might enhance the chemosensitivity of GBC-SD cells to doxorubin through arresting the cell cycle at S phase, but not P53 and Bax protein induced cell apoptosis.

Expression of the Somatostatin Receptor in GBC-SD Cell Lines and Its Significance

Somatostatin Enhances the Chemosensitivity of Gbc-Sd Cell Line to Doxorubicin Through Arresting the Cell Cycle to S Phase Rather Than Through the P53/Bax-Depended Apoptosis Way in Vitro

Mechanism Research in Somatostatin Reverting the Chemosensitivity of GBC-SD Cell Line

The Mechanisms of Somatostatin Induced Enhanced Chemosensitivity of Gallbladder Cancer Cell Line to Doxorubicin: Cell Cycle Modulation Plus Target Enzyme Up-Regulation.

[Somatostatin Enhanced Anti-Tumor Effect of Doxorubicin on Gallbladder Cancer Cells Through the Regulation of Intracellular Drug Concentration].

Somatostatin May Enhance Cytotoxic Effect of Doxorubicin on Gallbladder Cancer Cells

The Synergistic Inhibitory Effect of Somatostatin-Doxorubicin Co-Treatment on Gallbladder Carcinoma

Somatostatin Elevates Topoisomerase Ii Alpha and Enhances the Cytotoxic Effect of Doxorubicin on Gallbladder Cancer Cells

Expression of somatostatin receptors in nasopharyngeal carcinoma cell line CNE2

The expression of survivin in human gastric carcinoma and precancerous lesions.

Expression of Somatostatin Receptor Mrna in Human Pancreatic Cancer and Its Signification

Expression of Somatostatin Receptor Subtypes in Human Pancreatic Cancer

Mrna Expression of Somatostatin Receptor Subtypes SSTR-2, SSTR-3, and SSTR-5 and Its Significance in Pancreatic Cancer

Expression of somatostatin receptor in human colorectal cancers and normal mucous tissues

Somatostatin Enhances Antitumor Effect of Doxorubicin on Gallbladder Caner Cell

REGULATION ON GALLBLADDER CANCER CELL CYCLE REVERT ITS CHEMORESISTANCE ON DOXORUBICIN IN VITRO & IN VIVO

The Effect of Somatostatin and SSTR3 on Proliferation and Apoptosis of Gastric Cancer Cells

Study on Mrna Expressions of Subtypes of Somatostatin Receptors in Gastric Carcinoma

The differential expression of somatostastin receptors in hepatocellular carcinoma HCCLM3 cell lines

Gallbladder Cancer Cells Express 3 Subtypes of Somatostatin Receptors and Respond Better to the Treatment of Cytotoxic Drugs Combined with Somatostatin

Somatostatin Receptors in Gastrointestinal Stromal Tumors: New Prognostic Biomarker and Potential Therapeutic Strategy.